Ligand Pharma Form 4 Filings

LIGAND PHARMACEUTICALS INC’s Chief Financial Officer, Octavio Espinoza, reported option-related transactions and a share sale on August 12, 2026. He exercised stock options covering 31,641 shares of common stock at exercise prices between $52.84 and $70.04 per share, then sold 31,641 shares of common stock at a weighted-average price of $292.065 per share in multiple transactions. The company notes these trades were made under a written Rule 10b5-1 trading plan adopted on May 13, 2026.

Ligand Pharmaceuticals director Jason Haas reported an option exercise and share sale dated August 12, 2026. He exercised a Non-Qualified Stock Option for 6,138 shares of common stock at an exercise price of $51.56 per share, fully disposing of this option grant. He then reported acquiring 6,138 common shares from the exercise and selling 7,138 common shares at a weighted-average price of $292.8078 per share, with individual sale prices ranging from $292.5000 to $292.8550. The Rule 10b5-1 trading-plan checkbox was not marked for these transactions.

LIGAND PHARMACEUTICALS INC officer Andrew Reardon, CLO & Secretary, exercised 5,000 employee stock options at $52.2700 per share on August 3, 2026, receiving 5,000 common shares. That same day he sold 5,000 common shares in multiple transactions at weighted-average prices within disclosed ranges from $283.24 to $292.89 per share. After the exercise, the option grant expiring 2032-08-01 covers 29,444.0000 shares. All reported transactions were made under a written trading plan adopted November 24, 2025, in accordance with Rule 10b5-1.

Ligand Pharmaceuticals CLO & Secretary Andrew Reardon reported an exercise-and-sell transaction in company stock. On July 1, 2026, he exercised 5,000 stock options at $52.27 per share and sold 5,000 shares of common stock in multiple open-market trades at prices generally around the low-to-mid $300s. The filing notes these transactions were made under a pre-arranged Rule 10b5-1 trading plan. On June 30, 2026, he also acquired 132 shares through the Ligand Employee Stock Purchase Plan in an exempt transaction, and he continues to hold a substantial direct equity stake after these trades.

Ligand Pharmaceuticals’ Chief Financial Officer Octavio Espinoza reported a small, routine share acquisition under an employee plan. On the transaction date, he acquired 17 shares of common stock at a price of $160.7095 per share through the Ligand Employee Stock Purchase Plan, in a transaction exempt under Rule 16b-3(d) and Rule 16b-3(c). Following this, he directly holds 27,696 shares of common stock, indicating the move is a minor adjustment within his overall equity position rather than a significant market transaction.

LIGAND PHARMACEUTICALS INC Chief Executive Officer Todd C. Davis recorded a small employee stock purchase transaction. On this Form 4, he acquired 132 shares of common stock at $160.7095 per share under the Ligand Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Following this routine plan purchase, he directly holds 199,513 common shares.

Ligand Pharmaceuticals director Stephen L. Sabba reported an exercise-and-sell stock transaction. He exercised a non-qualified stock option covering 2,145 shares of common stock at an exercise price of $66.13 per share and then sold 2,145 shares in an open-market transaction at $254.00 per share on June 16, 2026.

Following these transactions, Sabba directly holds 33,629 shares of Ligand common stock. The exercised option grant, originally for 2,456 shares and later adjusted to 2,145 shares with a $66.13 exercise price after the OmniAb Inc. separation, has been fully exercised, leaving no remaining derivative position from that grant.

Ligand Pharmaceuticals director Jason Haas reported a combination of option exercises and share sales in the company’s stock. On June 12, 2026, he sold a total of 6,461 shares of common stock in open-market transactions, with weighted-average prices around $255.01 and $256.08. According to footnotes, these sales occurred in multiple trades within price ranges of $255.00–$255.29 and $256.00–$256.51.

On the same date, Haas exercised non-qualified stock options covering 4,000 shares of common stock at an exercise price of $51.56 per share, converting derivative awards into directly held shares. The filing shows both the sales and the option exercises as direct ownership transactions.

Funds managed by entities associated with director Jason Aryeh reported open-market sales totaling 5,000 shares of Ligand Pharmaceuticals common stock at $250 per share on June 10–11, 2026, leaving 102,580 shares held directly and 13,000 shares held indirectly.

On June 5, 2026, the funds also received 836 restricted stock units (RSUs), each representing one common share, which fully vest on the earlier of the next annual stockholder meeting or the first anniversary of grant. In addition, they were granted 2,938 non-qualified stock options exercisable for common stock at $237 per share, expiring on June 5, 2036.

The filing notes the total number of shares previously reported was reduced by 7,825 shares to align with the reporting person's account records and clarifies that all securities are owned by funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates, for which Aryeh may be deemed a beneficial owner.

LIGAND PHARMACEUTICALS INC director John L. Lamattina reported selling 4,591 shares of Common Stock on June 10, 2026 in a series of open-market transactions. The reported weighted-average sale prices ranged from about $246.63 to $251.90 per share across the different trades.

Individual transactions included sales such as 3,405 shares at a weighted-average price of $251.6158 and smaller blocks at prices around $247–$250 per share. Following these sales, he directly holds 26,969 shares of Ligand Pharmaceuticals Common Stock.

LIGAND PHARMACEUTICALS INC director Martine Zimmermann reported routine equity compensation and related tax withholding. She received 836 restricted stock units, each convertible into one share of common stock, granted by the board on June 5, 2026. These RSUs fully vest on the earlier of the next annual stockholder meeting or the first anniversary of the grant date. The company also granted her non-qualified stock options for 2,938 shares at an exercise price of $237.00 per share, with the same vesting schedule and expiration in 2036. To cover taxes on RSU settlement, 182 shares of common stock were withheld, a non-market disposition. After these transactions, she directly holds 5,097 common shares and 2,938 options.

Sabba Stephen L reported acquisition or exercise transactions in this Form 4 filing.

Ligand Pharmaceuticals director Stephen L. Sabba received new equity awards. On June 5, 2026, he was granted 836 restricted stock units, each representing one share of common stock, and 2,938 non-qualified stock options with a strike price of $237.00 per share.

Both the RSUs and options fully vest on the earlier of the company’s next annual stockholder meeting following the grant date or the first anniversary of the grant date. Following the stock grant, Sabba directly holds 33,629 shares of Ligand common stock, plus the newly granted options expiring on June 5, 2036.

LIGAND PHARMACEUTICALS INC director John L. Lamattina received equity awards from the board on June 5, 2026. He was granted 836 restricted stock units, each representing one share of common stock, increasing his direct common stock holdings to 31,560 shares.

He was also granted a Non-Qualified Stock Option for 2,938 shares of common stock at an exercise price of 237.0000 per share, expiring on June 5, 2036. Both the RSUs and the option award fully vest on the earlier of the next annual meeting of company stockholders following the grant date or the first anniversary of the grant date.

Ligand Pharmaceuticals director John W. Kozarich received new equity awards as part of his board compensation. On June 5, 2026, he was granted 836 restricted stock units, each representing one share of common stock, and a non-qualified stock option for 2,938 shares at an exercise price of $237.00 per share. Both awards fully vest on the earlier of the company’s next annual stockholder meeting following the grant date or the first anniversary of the grant date. Following these grants, Kozarich directly holds 42,622 shares of Ligand common stock.

Ligand Pharmaceuticals director Jason Haas received equity awards as part of board compensation. He acquired 836 restricted stock units, each representing one share of common stock, bringing his direct common stock holdings to 7,442 shares. He also received a non-qualified stock option for 2,938 shares at an exercise price of $237 per share, expiring on June 5, 2036. Both the RSUs and options fully vest on the earlier of the company’s next annual stockholder meeting following the grant date or the first anniversary of the June 5, 2026 grant.

Ligand Pharmaceuticals director Nancy Ryan Gray received new equity awards. She was granted 836 restricted stock units of common stock, which fully vest on the earlier of the next annual stockholder meeting or the first anniversary of the June 5, 2026 grant date.

Gray was also granted a non-qualified stock option for 2,938 shares of common stock at an exercise price of $237.00 per share, expiring on June 5, 2036. Following these grants, she holds 8,930 shares of common stock directly and 2,938 outstanding stock options.

Ligand Pharmaceuticals’ CLO and Secretary Andrew Reardon reported a set of planned insider trades in company common stock. On June 1, 2026, he exercised employee stock options for 5,000 shares at an exercise price of $52.27 per share, converting them into common stock.

On the same date, he executed open‑market sales totaling 5,000 shares of common stock in multiple transactions, at reported weighted‑average prices that include $230.41, $229.47, $228.57 and $223.95 per share. After these transactions, he directly holds 41,382 shares of Ligand common stock. The filing notes that these trades were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 24, 2025.

Ligand Pharmaceuticals’ Chief Financial Officer Octavio Espinoza exercised employee stock options to acquire 1,736 shares of Common Stock on May 27, 2026. He exercised 972 options at an exercise price of $52.84 per share and 764 options at $63.62 per share. Following these transactions, he directly holds 27,679 Common Shares. The filing also shows 17,407 employee stock options remaining outstanding at a $63.62 exercise price, with expirations in 2032, reflecting routine compensation-related equity activity rather than open‑market buying or selling.

LIGAND PHARMACEUTICALS INC director John W. Kozarich reported a combination of option exercises and open-market sales of common stock. He exercised non-qualified stock options covering 2,034 shares at an exercise price of $69.5100 per share and sold 2,501 shares in multiple transactions at prices around $223–$234 per share. The filing shows he directly owned 41,786 common shares after the reported transactions. All trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2025, indicating they were scheduled in advance rather than timed discretionarily.

Ligand Pharmaceuticals’ CLO & Secretary Andrew Reardon reported a pre-planned option exercise and share sale. On May 1, 2026, he exercised employee stock options for 5,000 shares of common stock at $52.27 per share and sold 5,000 shares of common stock in open-market transactions at weighted-average prices ranging from about $227 to $234 per share. The filing notes these trades were made under a Rule 10b5-1 trading plan adopted on November 24, 2025, indicating they were scheduled in advance rather than timed discretionarily.

Ligand Pharmaceuticals director John W. Kozarich reported selling a total of 467 shares of common stock on April 1, 2026 in a series of open-market transactions. The reported weighted-average sale prices ranged from about $199.97 to $204.26 per share.

These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2025. After the sales, Kozarich directly holds 42,253 shares of Ligand Pharmaceuticals common stock.

Ligand Pharmaceuticals’ CLO & Secretary Andrew Reardon exercised stock options and sold the resulting shares. He exercised 5,000 Employee Stock Options at an exercise price of $52.27 per share, receiving 5,000 shares of common stock.

On the same date, he sold all 5,000 shares in multiple open-market transactions at weighted-average prices ranging from about $198.40 to $204.82 per share, under a written Rule 10b5-1 trading plan adopted on November 24, 2025. Following these transactions, he directly holds 41,382 shares of Ligand common stock.

Director John L. LaMattina of LIGAND PHARMACEUTICALS INC exercised stock options and sold the resulting shares. He exercised a non-qualified stock option for 2,161 shares of common stock at an exercise price of $114.15 per share, then sold 2,161 shares of common stock in an open-market transaction at $200.76 per share on the same day. Following these transactions, he directly holds 30,724 shares of Ligand common stock. The option position associated with these 2,161 shares is now fully exercised.

Ligand Pharmaceuticals’ Chief Financial Officer Octavio Espinoza received equity awards as part of his compensation. He was granted stock options covering 23,527 shares of common stock at an exercise price of $202.55 per share, expiring on March 2, 2036. These options vest as to 12.5% of the underlying shares six months after the grant date, then in 42 substantially equal monthly installments.

He also received 4,933 restricted stock units (RSUs), each representing one share of common stock. The RSUs vest in three substantially equal annual installments on February 15, 2027, February 15, 2028, and February 15, 2029, subject to continued service. Delivery of shares on each vesting date will be deferred under the company’s Nonqualified Deferred Compensation Plan. Following the RSU grant, he directly owns 37,945 shares of common stock.

Ligand Pharmaceuticals Chief Executive Officer Todd C. Davis reported equity awards consisting of stock options and restricted stock units. He received options to buy 50,058 shares of common stock at an exercise price of $202.55 per share, expiring on March 2, 2036.

The option grant vests as to 12.5% of the underlying shares six months after the grant date and then in 42 substantially equal monthly installments. Davis also received 10,495 restricted stock units, each representing one share of common stock, which vest in three equal annual installments on February 15, 2027, February 15, 2028, and February 15, 2029, with delivery of shares deferred under a company plan.

Ligand Pharmaceuticals’ CLO & Secretary Andrew Reardon reported equity compensation awards. He received 4,513 shares of common stock as a grant, bringing his direct common stock holdings to 41,382 shares.

He was also granted an option for 21,525 shares at an exercise price of 202.55 per share. The option vests 12.5% six months after the March 2, 2026 grant date and then in 42 equal monthly installments. The 4,513-share grant represents restricted stock units that vest in three equal annual installments on February 15, 2027, February 15, 2028, and February 15, 2029, with delivery of shares deferred under a company plan.

Ligand Pharmaceuticals director Stephen L. Sabba reported an open-market sale of 1,000 shares of Common Stock. The shares were sold on March 23, 2026 at an average price of $207.8727 per share, as detailed across multiple small trades that day.

After this transaction, Sabba directly holds 32,793 shares of Ligand Pharmaceuticals Inc. A footnote explains that this total includes 1,209 previously reported restricted shares that were granted in 2025 and are expected to vest in full within six months from the reported date.

Ligand Pharmaceuticals’ Chief Financial Officer Octavio Espinoza exercised employee stock options and sold shares in the company on March 11, 2026. He exercised options covering 2,405 shares of common stock at an exercise price of $92.65 per share.

On the same day, he sold 3,057 shares of common stock at a price of $225.00 per share, leaving him with 21,010 shares held directly after the transactions. These trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025, and the stock option was fully vested and exercisable.

Ligand Pharmaceuticals’ Chief Legal Officer and Secretary Andrew Reardon reported a set of planned insider transactions in company stock. On March 4, 2026, he exercised employee stock options for 5,000 shares of common stock and then sold 5,000 common shares in a series of open-market trades.

The sales were executed at weighted-average prices disclosed in ranges between approximately $197.58 and $208.97, under a Rule 10b5-1 trading plan adopted on November 24, 2025. After these transactions, Reardon directly holds 36,869 common shares and 54,444 options, with the underlying option grant vesting over time.

Ligand Pharmaceuticals’ Chief Financial Officer Octavio Espinoza reported option exercises and share sales in company stock. On March 4, 2026, he exercised employee stock options covering 2,073 shares of common stock and then sold 13,423 shares in open-market transactions.

The sales were executed at weighted-average prices generally between $198.37 and $208.95 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. After these transactions, he directly owned 21,662 shares of Ligand common stock.

Ligand Pharmaceuticals director Stephen L. Sabba exercised a stock option for 2,034 common shares at $69.51 per share and on the same day sold 2,034 shares at $201.50 per share in an open-market transaction. He now directly holds 33,793 common shares.

Ligand Pharmaceuticals director John W. Kozarich reported open-market sales of company common stock. On March 2, 2026, he sold a total of 467 shares in six separate transactions under a written trading plan adopted on March 7, 2025 in accordance with Rule 10b5-1.

The reported weighted-average prices for these sales ranged from about $197 to $203 per share, based on detailed price ranges in the filing. After completing the transactions, Kozarich directly owned 42,720 shares of Ligand Pharmaceuticals common stock.

Ligand Pharmaceuticals’ CLO & Secretary Andrew Reardon reported equity compensation activity and related tax withholding in company stock. On February 14, 2026, he acquired 6,928 and 8,810 shares of common stock at no cost through grants tied to performance stock units and restricted stock units.

On February 14–15, 2026, several transactions coded “F” show blocks of common shares, including 3,211 and 4,083 shares at $183.83 per share, being withheld by the issuer to cover tax liabilities from these equity awards, rather than open‑market sales.

Ligand Pharmaceuticals Chief Financial Officer equity transactions center on PSU and RSU settlements and related tax withholding. On February 14, Octavio Espinoza acquired 7,390 and 8,810 shares of common stock at $0 per share through grants tied to performance and restricted stock units. On February 14–15, he disposed of a total of 11,763 shares at $183.83 per share in tax-withholding dispositions, where shares were withheld by the issuer to cover tax liabilities.

Ligand Pharmaceuticals CEO Todd C. Davis reported equity compensation activity involving common stock. On February 14, 2026, he acquired 20,782 and 39,644 shares at $0.00 per share as grants tied to performance and restricted stock units. On February 14–15, 2026, a total of 32,877 shares at $183.83 per share were disposed of as share-withholding transactions to cover tax liabilities upon PSU and RSU settlement. After these transactions, his directly owned holdings remained in the mid‑190,000 share range across the reported rows.

Ligand Pharmaceuticals director John W. Kozarich sold 467 shares of common stock in a planned transaction. The sales occurred on February 2, 2026 at prices ranging from $191.00 to $197.195 per share in several small trades.

After these sales, Kozarich directly beneficially owned 43,187 shares of Ligand common stock. The filing notes that the transactions were executed under a written trading plan adopted on March 7, 2025 in accordance with Rule 10b5-1, which allows pre-arranged trading by insiders.

Ligand Pharmaceuticals director John W. Kozarich reported multiple small open‑market sales of company common stock. On January 2, 2026, he sold an aggregate of 467 shares in a series of transactions at weighted‑average prices ranging from $186.59 to $192.395 per share.

The filing shows these trades were executed under a pre‑arranged written trading plan adopted on March 7, 2025 in accordance with Rule 10b5‑1, which is designed to allow insiders to sell shares according to a set schedule. After these sales, Kozarich directly beneficially owns 43,654 shares of Ligand common stock.

Ligand Pharmaceuticals’ Chief Financial Officer, Octavio Espinoza, reported multiple stock option exercises on December 16, 2025. He acquired a total of 2,381 shares of common stock through option exercises at strike prices of $52.84, $57.22, $63.62, $92.65, and $103.42 per share. Following these transactions, he directly beneficially owned 28,567 shares of Ligand common stock. The exercised options were granted under several employee stock option awards with vesting schedules running through 2025 and expiration dates between 2028 and 2032.

Ligand Pharmaceuticals reported an insider stock sale by its chief financial officer, Octavio Espinoza. In the transaction dated 12/12/2025, he sold 1,804 shares of the company’s common stock at a price of $188.31 per share, coded as a sale in the regulatory report.

Following this transaction, Espinoza beneficially owns 26,186 shares of Ligand Pharmaceuticals common stock in direct ownership. The report is filed as an individual filing by one reporting person in his capacity as an officer and chief financial officer.

Ligand Pharmaceuticals Inc. Chief Executive Officer and director Todd C. Davis reported a bona fide gift of 130 shares of common stock on 12/04/2025.

The shares were given to a charitable entity and are reported at a price of $0.0, reflecting the gift nature of the transaction. Following this transfer, Davis directly beneficially owns 161,337 shares of Ligand common stock.

Ligand Pharmaceuticals (LGND) director John L. LaMattina reported same‑day option exercises and share sales. On 11/07/2025, he exercised 2,145 options at $66.13 and 2,034 options at $69.51, then sold 2,145 shares at $205.45 and 2,034 shares at $205.45. Following these transactions, he directly owned 30,724 shares. The options exercised were previously granted awards that had been adjusted in connection with the OmniAb Inc. separation and carried expiration dates of 05/25/2027 and 05/23/2026.

Ligand Pharmaceuticals (LGND): Form 4 insider transaction

Director John W. Kozarich reported open‑market sales of Ligand common stock on 11/03/2025 pursuant to a Rule 10b5‑1 trading plan adopted on March 07, 2025. Reported sales were executed in multiple trades: 84 shares at a weighted‑average price of $188.9968, 49 shares at $190.2579, 207 shares at $191.2494, and 127 shares at $192.3781. Following these transactions, the reporting person beneficially owned 44,588 shares, held directly. Prices reflect weighted averages across multiple executions within disclosed ranges.

Ligand Pharmaceuticals (LGND) reported an insider transaction by director John W. Kozarich. On 10/01/2025, he executed multiple open-market sales of common stock under a Rule 10b5-1 trading plan adopted on March 07, 2025.

Sales were small blocks of 24, 196, 155, and 92 shares at weighted-average prices of $177.6048, $178.4051, $180.0098, and $181.1838, respectively. Following these transactions, he directly beneficially owned 45,055 shares.

Footnotes state the prices reflect weighted averages across multiple trades within disclosed price ranges, with full breakdowns available upon request. The filing lists the reporting person as a Director with direct ownership.

Jason Aryeh, a director of Ligand Pharmaceuticals (LGND), reported the sale of 10,000 shares of Ligand common stock on 09/23/2025. The sales occurred in multiple transactions at weighted-average prices reported in three groupings: $170.4051 (range $169.6625–$170.6600), $170.9643 (range $170.6850–$171.6050), and $171.9237 (range $171.7250–$172.2400).

After these transactions Mr. Aryeh directly beneficially owned between 69,289 and 74,871 shares across the reported lines and retains indirect holdings of 51,594 shares through funds managed by JALAA Equities, LP/JLV Investments, LP and 5,025 shares held by a trust. The Form 4 was signed on 09/24/2025 by an attorney-in-fact.

Martine Zimmermann, a director of Ligand Pharmaceuticals (LGND), reported a disposal of company common stock related to tax withholding on 09/22/2025. The Form 4 shows 115 shares were withheld at an effective price of $170.77 per share to satisfy tax obligations arising from the settlement of restricted stock units, leaving Ms. Zimmermann with 4,443 shares beneficially owned on a direct basis. The filing was signed by an attorney-in-fact on behalf of the reporting person on 09/24/2025. The entry is a routine insider tax-withholding transaction rather than an active market sale.